Sign In
Buy GPCR
$45.51
+1.00 (+2.25%)
At Close: Jun 22, 2026
The Next Phase Of The Obesity Drug Race
02:00pm, Saturday, 13'th Jun 2026
Five years after Wegovy's FDA approval, the obesity drug market has evolved rapidly. Novo Nordisk and Eli Lilly introduced GLP-1 pills this year and others like Structure Therapeutics and Zealand Phar
Structure Therapeutics: My Top Small-Cap Pick For The Obesity Market (Upgrade)
01:03pm, Thursday, 11'th Jun 2026
Structure Therapeutics advances aleniglipron, a potential best-in-class oral GLP-1, into Phase 3 for obesity, supported by strong Phase 2b data. GPCR's $1.5B cash position and a projected cash runway
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
12:52pm, Tuesday, 09'th Jun 2026
Structure Therapeutics Inc. (GPCR) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Structure's experimental obesity pill shows no signs of liver injury
05:16pm, Friday, 05'th Jun 2026
Structure Therapeutics said on Friday its experimental GLP-1 obesity pill did not show any signs of drug-induced liver injury, and patients continued to lose weight even on the lower doses of the d
Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity
04:05pm, Friday, 05'th Jun 2026
Publication presented concurrently with oral presentation at American Diabetes Association's 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecul
Structure Therapeutics Announces Participation in Upcoming Investor Conferences
04:05pm, Tuesday, 26'th May 2026
SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for meta
If Viking Therapeutics Is Acquired, Here’s Who Wins
08:50am, Tuesday, 26'th May 2026
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with a
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
10:19am, Sunday, 24'th May 2026
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.
Can Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?
12:36pm, Thursday, 21'st May 2026
Eli Lilly's GLP-1 portfolio is driving growth in 2026, with Mounjaro, Zepbound and Foundayo gaining traction across obesity, diabetes and related markets.
Monashee Scales Back Its Bet on Structure Therapeutics
03:27pm, Wednesday, 20'th May 2026
This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.
This Obesity Drug Stock Has Jumped 60% as Phase 3 Plans Advance. A Fund Just Sold $4.7 Million
02:22pm, Sunday, 17'th May 2026
This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and pulmonary targets.
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?
11:20am, Thursday, 14'th May 2026
NVO beats Q1 estimates and raises its 2026 outlook. Meanwhile, Eli Lilly's expanding GLP-1 portfolio threatens its obesity market dominance.
Lilly Bets on Next-Generation Obesity Drugs to Stay Ahead
12:52pm, Wednesday, 13'th May 2026
LLY expands beyond tirzepatide with oral obesity pills and next-gen drugs like retatrutide to defend its lead in the booming weight-loss market.
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing
02:35am, Monday, 11'th May 2026
Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) entered into a license agreement with a newly established c
Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
04:05pm, Thursday, 07'th May 2026
Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially co
